Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gedeon Richter PLC (GEDSF)
Budapest, BU, HU
Gedeon Richter Plc is a company focused on the development and manufacturing of pharmaceutical products. Its operations are organized into three primary divisions: Pharmaceuticals, Wholesale & Retail, and Other. The Pharmaceutical segment covers all aspects from the research and development of new drugs and their production, through to their sales and marketing. The Wholesale & Retail division is responsible for distributing the company's products to consumers via its network of affiliated companies and pharmacies across various regional markets. The Other segment includes services provided by group members that support marketing and sales activities. The company was established in 1901 by Gedeon Richter and is headquartered in Budapest, Hungary.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +27.76% | -11.57% | +29.09% | +275.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Pharmaceuticals: +7.8%+0.6% Q1'26: 0.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-9.8% Q1'26: -2.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+19.2% Q1'26: +35.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+34.9% ★ Q1'26: +32.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+21.0% ★ Q1'26: +20.9% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.1% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.06× ★ Q1'26: 0.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. |
Dec 2027 6 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
857.55B
est: 863.35B (-0.7%)
|
862.58B
est: 925.34B (-6.8%)
|
951.72B
934.35B – 1.01T
+2.9% YoY
|
1.02T
978.78B – 1.09T
+7.5% YoY
|
| EBITDA |
342.57B
est: 484.60B (-29.3%)
|
356.73B
est: 519.40B (-31.3%)
|
534.21B
524.46B – 565.80B
+2.9% YoY
|
574.52B
549.40B – 614.52B
+7.5% YoY
|
| EBIT |
293.05B
est: 429.78B (-31.8%)
|
300.59B
est: 460.64B (-34.7%)
|
473.77B
465.12B – 501.79B
+2.9% YoY
|
509.53B
487.24B – 545.00B
+7.5% YoY
|
| Net Income |
239.24B
|
215.73B
|
—
— – —
|
—
— – —
|
| SGA |
220.99B
est: 209.71B (+5.4%)
|
222.79B
est: 224.77B (-0.9%)
|
231.18B
226.96B – 244.85B
+2.9% YoY
|
248.62B
237.75B – 265.93B
+7.5% YoY
|
| EPS |
1,307.00
|
1,178.67
|
—
— – —
|
—
— – —
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gabor Orban | CEO & Director | 165M | male |
| Laszlo Andras Kovacs | Group Head of Controlling, Chief Financial Officer & Director | 89M | male |
| Katalin Erdei | Human Resources & Technical Director | — | female |
| Robert Rethy | Head of the Investor Relations & ESG Department | — | male |
| Tamas Szolyak | Director of Global Regulatory Science, Commerce & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GEDSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
